ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression

Nature Medicine

Volumn 18, Issue 1, 2012, Pages 128-134

  Hoetzenecker, Wolfram ^a   Echtenacher, Bernd ^b   Guenova, Emmanuella ^a   Hoetzenecker, Konrad ^c   Woelbing, Florian ^a   Brück, Jürgen ^a   Teske, Anna ^a   Valtcheva, Nadejda ^d   Fuchs, Kerstin ^a   Kneilling, Manfred ^a   Park, Ji Hyeon ^e   Kim, Kyu Han ^e   Kim, Kyu Won ^e,f   Hoffmann, Petra ^g   Krenn, Claus ^c   Hai, Tsonwin ^h   Ghoreschi, Kamran ^a   Biedermann, Tilo ^a   Röcken, Martin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ETH ZURICH   (Switzerland)

^e Seoul National University   (South Korea)

^f Seoul National University   (South Korea)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ENDOTOXIN; GLUTATHIONE; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL PERITONITIS; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI INFECTION; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; INNATE IMMUNITY; MONOCYTE; MOUSE; MYCOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SECONDARY INFECTION; SEPSIS; SEPSIS ASSOCIATED IMMUNOSUPPRESSION; SEPTIC SHOCK; WILD TYPE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; COINFECTION; FEMALE; GENE EXPRESSION REGULATION; GLUTATHIONE; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-6; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MONOCYTES; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS); MUS;

EID: 84855548457     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2557     Document Type: Article

References (54)

1. Martin, G.S., Mannino, D.M., Eaton, S. & Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003). (Pubitemid 36437931)
2. Riedemann, N.C., Guo, R.F. & Ward, P.A. Novel strategies for the treatment of sepsis. Nat. Med. 9, 517-524 (2003). (Pubitemid 36597096)
3. Hotchkiss, R.S. & Opal, S. Immunotherapy for sepsis-a new approach against an ancient foe. N. Engl. J. Med. 363, 87-89 (2010).
4. Bone, R.C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 136, e28 (2009).
5. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008). (Pubitemid 351512299)
6. Bone, R.C. et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317, 653-658 (1987). (Pubitemid 17138189)
7. Ziegler, E.J. et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324, 429-436 (1991).
8. Fisher, C.J. Jr. et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697-1702 (1996). (Pubitemid 26193621)
9. Abraham, E. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. J. Am. Med. Assoc. 273, 934-941 (1995).
10. Fisher, C.J. Jr. et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebocontrolled multicenter trial. Crit. Care Med. 22, 12-21 (1994).
11. Hotchkiss, R.S. & Karl, I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003). (Pubitemid 36056721)
12. Ward, N.S., Casserly, B. & Ayala, A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin. Chest Med. 29, 617-625 (2008).
13. Muller Kobold, A.C. et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med. 26, 883-892 (2000). (Pubitemid 30616041)
14. Hotchkiss, R.S. et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA 96, 14541-14546 (1999). (Pubitemid 30000686)
15. Osuchowski, M.F., Welch, K., Siddiqui, J. & Remick, D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177, 1967-1974 (2006). (Pubitemid 44092537)
16. Gogos, C.A., Drosou, E., Bassaris, H.P. & Skoutelis, A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181, 176-180 (2000). (Pubitemid 30049046)
17. Steinhauser, M.L. et al. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J. Immunol. 162, 392-399 (1999). (Pubitemid 29018946)
18. Gilchrist, M. et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441, 173-178 (2006).
19. Whitmore, M.M. et al. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J. Immunol. 179, 3622-3630 (2007).
20. Rosenberger, C.M., Clark, A.E., Treuting, P.M., Johnson, C.D. & Aderem, A. ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells. Proc. Natl. Acad. Sci. USA 105, 2544-2549 (2008). (Pubitemid 351520550)
21. Gilchrist, M. et al. Activating transcription factor 3 is a negative regulator of allergic pulmonary inflammation. J. Exp. Med. 205, 2349-2357 (2008).
22. Hai, T., Wolfgang, C.D., Marsee, D.K., Allen, A.E. & Sivaprasad, U. ATF3 and stress responses. Gene Expr. 7, 321-335 (1999). (Pubitemid 29372076)
23. Biolo, G., Antonione, R. & De Cicco, M. Glutathione metabolism in sepsis. Crit. Care Med. 35, S591-S595 (2007). (Pubitemid 47312200)
24. Fläring, U.B., Hebert, C., Wernerman, J., Hammarqvist, F. & Rooyackers, O.E. Circulating and muscle glutathione turnover in human endotoxaemia. Clin. Sci. (Lond.) 117, 313-319 (2009).
25. Chan, K., Han, X.D. & Kan, Y.W. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA 98, 4611-4616 (2001). (Pubitemid 32295024)
26. Kim, K.H., Jeong, J.Y., Surh, Y.J. & Kim, K.W. Expression of stress-response ATF3 is mediated by Nrf2 in astrocytes. Nucleic Acids Res. 38, 48-59 (2010).
27. Echtenacher, B., Mannel, D.N. & Hultner, L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381, 75-77 (1996). (Pubitemid 26130005)
28. Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339-342 (1994). (Pubitemid 24104268)
29. Kneilling, M. et al. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum. 56, 1806-1816 (2007). (Pubitemid 47110380)
30. Annane, D., Bellissant, E. & Cavaillon, J.M. Septic shock. Lancet 365, 63-78 (2005).
31. Benjamim, C.F., Hogaboam, C.M., Lukacs, N.W. & Kunkel, S.L. Septic mice are susceptible to pulmonary aspergillosis. Am. J. Pathol. 163, 2605-2617 (2003). (Pubitemid 37466501)
32. Benjamim, C.F., Hogaboam, C.M. & Kunkel, S.L. The chronic consequences of severe sepsis. J. Leukoc. Biol. 75, 408-412 (2004). (Pubitemid 38316370)
33. Akram, A. et al. Activating transcription factor 3 confers protection against ventilator induced lung injury. Am. J. Respir. Crit. Care Med. 182, 489-500 (2010).
34. Li, H.F., Cheng, C.F., Liao, W.J., Lin, H. & Yang, R.B. ATF3-mediated epigenetic regulation protects against acute kidney injury. J. Am. Soc. Nephrol. 21, 1003-1013 (2010).
35. Tsung, A. et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 204, 2913-2923 (2007). (Pubitemid 350179560)
36. Gill, R., Tsung, A. & Billiar, T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic. Biol. Med. 48, 1121-1132 (2010).
37. Marino, M.W. et al. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94, 8093-8098 (1997). (Pubitemid 27343782)
38. Beutler, B., Milsark, I.W. & Cerami, A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869-871 (1985). (Pubitemid 16246587)
39. Fattori, E. et al. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 180, 1243-1250 (1994). (Pubitemid 24289598)
40. Villa, P., Saccani, A., Sica, A. & Ghezzi, P. Glutathione protects mice from lethal sepsis by limiting inflammation and potentiating host defense. J. Infect. Dis. 185, 1115-1120 (2002). (Pubitemid 34297769)
41. Ortolani, O. et al. The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock. Am. J. Respir. Crit. Care Med. 161, 1907-1911 (2000). (Pubitemid 30418128)
42. Alves-Filho, J.C. et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16, 708-712 (2010).
43. Döcke, W.D. et al. Monocyte deactivation in septic patients: restoration by IFNgamma treatment. Nat. Med. 3, 678-681 (1997).
44. Deng, J.C. et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J. Clin. Invest. 116, 2532-2542 (2006). (Pubitemid 44330152)
45. Hoogerwerf, J.J. et al. Loss of suppression of tumorigenicity 2 (ST2) gene reverses sepsis-induced inhibition of lung host defense in mice. Am. J. Respir. Crit. Care Med. 183, 932-940 (2011).
46. Sultzer, B.M. Genetic control of leucocyte responses to endotoxin. Nature 219, 1253-1254 (1968).
47. Janeway, C.A. Jr. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002). (Pubitemid 34293424)
48. O'Brien, A.D. et al. Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J. Immunol. 124, 20-24 (1980). (Pubitemid 10166565)
49. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998). (Pubitemid 29001265)
50. Levy, M.M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 29, 530-538 (2003). (Pubitemid 36523666)
51. Hartman, M.G. et al. Role for activating transcription factor 3 in stress-induced beta-cell apoptosis Mol. Cell. Biol. 24, 5721-5732 (2004). (Pubitemid 38787958)
52. Ghoreschi, K. et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9, 40-46 (2003). (Pubitemid 36098258)
53. Biedermann, T. et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2, 1054-1060 (2001). (Pubitemid 33069501)
54. Ghoreschi, K. et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 208, 2291-2303 (2011).